

# CITATION REPORT

List of articles citing

**Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder**

**DOI: 10.1111/j.1743-6109.2010.02032.x**  
**Journal of Sexual Medicine, 2011, 8, 15-27.**

**Source:** <https://exaly.com/paper-pdf/51045319/citation-report.pdf>

**Version:** 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
251	Managing low sexual desire in women. <b>2011</b> , 7, 571-81; quiz 582-3		8
250	Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 1411-9	1.1	16
249	Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 3160-72	1.1	41
248	Facile Synthesis of N-{2-[4-(2-Pyrimidinyl)-1-Piperazinyl]ethyl} Adamantane-1-Carboxamide. <b>2011</b> , 117-119, 1319-1322		
247	Biased agonism at serotonin 5-HT <sub>1A</sub> receptors: preferential postsynaptic activity for improved therapy of CNS disorders. <b>2011</b> , 1, 149-164		69
246	Hypoactive sexual desire disorder. <b>2012</b> , 24, 215-20		4
245	Current world literature. <b>2012</b> , 24, 265-72		
244	The 5-HT <sub>1A</sub> -receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice. <b>2012</b> , 119, 1351-9		4
243	Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 3180-8	1.1	45
242	Testosterone supplementation for hypoactive sexual desire disorder in women. <b>2012</b> , 32, 38-53		12
241	Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 793-804	1.1	102
240	Flibanserin and 8-OH-DPAT implicate serotonin in association between female marmoset monkey sexual behavior and changes in pair-bond quality. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 694-707	1.1	23
239	Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 1074-85	1.1	106
238	Isolation and structural elucidation of flibanserin as an adulterant in a health supplement used for female sexual performance enhancement. <b>2012</b> , 57, 104-8		16
237	Brain neuronal activation induced by flibanserin treatment in female rats. <b>2013</b> , 230, 639-52		10
236	Chronic systemic administration of serotonergic ligands flibanserin and 8-OH-DPAT enhance HPA axis responses to restraint in female marmosets. <b>2013</b> , 38, 145-54		6
235	Standard operational procedures for low sexual desire in men. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 94-107		29

234	A standardized diagnostic interview for hypoactive sexual desire disorder in women: standard operating procedure (SOP Part 2). <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 50-7	1.1	25
233	Pharmacogenomics and sexuality: a vision. <b>2013</b> , 16 Suppl 1, 25-30		14
232	Flibanserin treatment increases appetitive sexual motivation in the female rat. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 1231-9	1.1	23
231	Motivated behaviors and levels of 3β-OHHP in the midbrain are attenuated by knocking down expression of pregnane xenobiotic receptor in the midbrain ventral tegmental area of proestrous rats. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 1692-706	1.1	13
230	Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 1807-15	1.1	118
229	Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health. <b>2013</b> , 33, 411-21		17
228	Brain region-specific transcriptomic markers of serotonin-1A receptor agonist action mediating sexual rejection and aggression in female marmoset monkeys. <i>Journal of Sexual Medicine</i> , <b>2013</b> , 10, 1461-75	1.1	18
227	Animal Models for the Study of Female Sexual Dysfunction. <b>2013</b> , 1, 108-122		15
226	Interest, Arousal, and Shifting Diagnoses of Female Sexual Dysfunction, or: How Women Learn About Desire. <b>2013</b> , 14, 187-205		13
225	Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists. <b>2014</b> , 5, 205		24
224	Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. <b>2014</b> , 21, 633-40		102
223	5-HT(1A) receptor: an old target as a new attractive tool in drug discovery from central nervous system to cancer. <b>2014</b> , 57, 4407-26		66
222	Pharmacology of serotonin and female sexual behavior. <b>2014</b> , 121, 31-42		26
221	Flibanserin-Stimulated Partner Grooming Reflects Brain Metabolism Changes in Female Marmosets. <i>Journal of Sexual Medicine</i> , <b>2015</b> , 12, 2256-66	1.1	1
220	Low sexual desire in women: amongst the confusion, could distress hold the key?. <b>2015</b> , 30, 338-350		7
219	Divergent effects of the 'biased' 5-HT1 A receptor agonists F15599 and F13714 in a novel object pattern separation task. <b>2015</b> , 172, 2532-43		30
218	Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. <b>2015</b> , 20, 1-6		167
217	Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women. <b>2015</b> , 16, 2523-9		12

216	The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder. <b>2015</b> , 29, 915-33	79
215	Flibanserin and Female Sexual Desire. <b>2016</b> , 20, 309-14	2
214	What History Can Teach Us About the Different Response to the Launch of Addyi Versus Viagra. <b>2016</b> , 8, 116-120	1
213	Flibanserin - the female Viagra?. <b>2017</b> , 21, 259-265	1
212	Next-day residual effects of flibanserin on simulated driving performance in premenopausal women. <b>2017</b> , 32, e2603	20
211	The pharmacodynamic effects of combined administration of flibanserin and alcohol. <b>2017</b> , 42, 598-606	63
210	Integrating Sexual Partners into Pharmacological Sex Therapy. <b>2017</b> , 453-467	1
209	Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Post Hoc Analysis. <b>2017</b> , 26, 1161-1168	6
208	Distressing Sexual Function at Midlife: Unmet Needs, Practical Diagnoses, and Available Treatments. <b>2017</b> , 130, 889-905	8
207	Die Lustpille für die Frau. <b>2017</b> , 15, 221-224	
206	Female Sexual Function. <b>2017</b> , 45-60	1
205	Female sexual dysfunction: a focus on flibanserin. <b>2017</b> , 9, 757-767	11
204	New developments in the treatment of hypoactive sexual desire disorder - a focus on Flibanserin. <b>2017</b> , 9, 171-178	3
203	Evaluation and Management of Hypoactive Sexual Desire Disorder. <b>2018</b> , 6, 59-74	24
202	Sexual Function Post-Breast Cancer. <b>2018</b> , 173, 167-189	8
201	Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. <b>2018</b> , 40, 64-73	8
200	Why the Sexual Tipping Point Is a Variable Switch Model <b>2018</b> , 10, 38-43	3
199	Flibanserin toxicity in a toddler following ingestion. <b>2018</b> , 56, 226-228	4

- 198 Drug-Associated Spontaneous Orgasm: A Case Report and Systematic Review of Literature. **2018**, 41, 31-37 3
- 197 Further Reading. **2018**, 455-508
- 196 Sexual Health in Women. **2018**, 27, 1082-1085
- 195 Pharmacosexology: Psychiatric Side Effects of Drugs for the Treatment of Sexual Dysfunction. **2018**, 225-249
- 194 A rapid and sensitive UPLC-MS/MS method for the determination of flibanserin in rat plasma: application to a pharmacokinetic study. **2019**, 13, 111 10
- 193 Safety and Tolerability of Evening Ethanol Consumption and Bedtime Administration of Flibanserin in Healthy Premenopausal Female Subjects. **2019**, 7, 418-424 4
- 192 New Treatments for Female Sexual Dysfunction: Are they Safe and Effective for Older Post-Menopausal Women?. **2019**, 11, 21-28
- 191 New dual ligands for the D and 5-HT receptors from the group of 1,8-naphthyl derivatives of LCAP. **2019**, 29, 2236-2242 5
- 190 Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder: Pooled Analysis of Clinical Trials. **2019**, 28, 769-777 83
- 189 Depression, Antidepressants, and Sexual Functioning. **2019**, 123-137 2
- 188 Four solid forms of flibanserin: Insight into the crystal structures, properties, stability, and solid-state transition. **2020**, 1199, 127042 3
- 187 Evaluation of safety for flibanserin. **2020**, 19, 1-8 8
- 186 Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin. **2020**, 15, 5253-5264 10
- 185 Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder. **2020**, 40, 560-567 4
- 184 Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment. **2020**, 29, 1101-1112 4
- 183 Mass Spectrometry-Based Rapid Quantitative Bioanalysis of Flibanserin: Pharmacokinetic and Brain Tissue Distribution Study in Female Rats. **2020**, 44, 559-569 10
- 182 Amalgamation of stress degradation and metabolite profiling in rat urine and feces for characterization of oxidative metabolites of flibanserin using UHPLC-Q-TOF-MS/MS, H/D exchange and NMR technique. **2020**, 1139, 121993 8
- 181 A novel design and facile synthesis of nature inspired poly (dopamine-Cr<sup>3+</sup>) nanocubes decorated reduced graphene oxide for electrochemical sensing of flibanserin. **2021**, 164, 106020 6

180	Translating biased agonists from molecules to medications: Serotonin 5-HT receptor functional selectivity for CNS disorders. <b>2021</b> , 107937	6
179	The Heteronormativity Theory of Low Sexual Desire in Women Partnered with Men. <b>2021</b> , 1	11
178	A mechanistic explanation on degradation behavior of flibanserin for identification and characterization of its potential degradants using LC-DAD/ESI/APCI-Q-TOF-MS/MS. <b>2021</b> , 167, 106281	4
177	Treatment of Hypoactive Sexual Desire Disorder Among Women: General Considerations and Pharmacological Options. <b>2021</b> , 19, 39-45	1
176	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. <b>2021</b> , 73, 310-520	48
175	Psychological Treatment of Low Sexual Desire in Women: Protocol for a Randomized, Waitlist-Controlled Trial of Internet-Based Cognitive Behavioral and Mindfulness-Based Treatments. <b>2020</b> , 9, e20326	7
174	Flibanserin: Approval of a controversial drug for a controversial disorder. <b>2015</b> , 57, 221-3	8
173	Psychosexual disorders and dermatologists. <b>2016</b> , 7, 149-58	6
172	Flibanserin: A controversial drug for female hypoactive sexual desire disorder. <b>2018</b> , 27, 154-157	13
171	Medikamente zur Behandlung sexueller Funktionsstörungen. <b>2012</b> , 751-763	
170	Female Sexual Dysfunction (FSD). <b>2015</b> , 147-168	
169	Sex and Pharmacological Sexual Enhancement. <b>2017</b> , 387-411	
168	Sexual Function and Alcohol and Other Drug Use. <b>2021</b> , 1225-1239	0
167	Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women. <b>2017</b> , 42, 237-241	6
166	Duloxetine. <b>2020</b> , 263-268	
165	Imipramine. <b>2020</b> , 367-374	
164	Paliperidone. <b>2020</b> , 581-592	
163	Molindone. <b>2020</b> , 527-532	

162 Diphenhydramine. **2020**, 235-238

161 Citalopram. **2020**, 159-164

160 Aripiprazole. **2020**, 53-64

159 Acamprosate. **2020**, 1-4

158 Atomoxetine. **2020**, 79-84

157 Carbamazepine. **2020**, 131-136

156 Flunitrazepam. **2020**, 297-300

155 Lumateperone. **2020**, 451-456

154 Galantamine. **2020**, 337-342

153 Flumazenil. **2020**, 293-296

152 Oxcarbazepine. **2020**, 575-580

151 Flupenthixol. **2020**, 307-312

150 Asenapine. **2020**, 71-78

149 Clozapine. **2020**, 191-200

148 Lofepamine. **2020**, 421-426

147 Armodafinil. **2020**, 65-70

146 Amoxapine.

145 Diazepam. **2020**, 229-234

144 Brexanolone. **2020**, 99-102

143 Escitalopram. **2020**, 269-274

142 Chlordiazepoxide. **2020**, 147-152

141 Lurasidone. **2020**, 457-464

140 Deutetrabenazine. **2020**, 221-224

139 Disulfiram. **2020**, 239-242

138 Nefazodone. **2020**, 545-550

137 Dothiepin. **2020**, 249-254

136 Lemborexant.

135 Mianserin. **2020**, 495-498

134 Moclobemide. **2020**, 515-520

133 Buspirone. **2020**, 123-126

132 Agomelatine.

131 Oxazepam. **2020**, 569-574

130 Naltrexone/Bupropion. **2020**, 541-544

129 Lithium. **2020**, 415-420

128 Introduction. **2020**, xi-xiv

127 Haloperidol. **2020**, 347-354



126 Desvenlafaxine. **2020**, 215-220

125 Desipramine. **2020**, 207-214

124 Memantine.

123 Olanzapine. **2020**, 559-568

122 Isocarboxazid. **2020**, 375-382

121 Nalmefene. **2020**, 533-536

120 Ketamine. **2020**, 383-386

119 Dextromethorphan. **2020**, 225-228

118 Clonazepam. **2020**, 173-178

117 Methylphenidate (D,L). **2020**, 487-494

116 Naltrexone. **2020**, 537-540

115 Levomilnacipran. **2020**, 403-408

114 lloperidone. **2020**, 359-366

113 Nortriptyline. **2020**, 551-558

112 Blonanserin. **2020**, 89-94

111 Gabapentin. **2020**, 331-336

110 Maprotiline. **2020**, 465-472

109 Amphetamine (D,L). **2020**, 45-52

108 Buprenorphine. **2020**, 111-116

107 Doxepin. **2020**, 255-262

106 Methylphenidate (D). **2020**, 481-486

105 Guanfacine. **2020**, 343-346

104 Methylfolate (L). **2020**, 477-480

103 Levetiracetam. **2020**, 399-402

102 Brexpiprazole.

101 Hydroxyzine. **2020**, 355-358

100 Esketamine. **2020**, 275-280

99 Cariprazine. **2020**, 137-146

1

98 Alprazolam. **2020**, 11-16

97 Estazolam. **2020**, 281-284

96 Lisdexamfetamine.

95 Donepezil. **2020**, 243-248

94 Bupropion. **2020**, 117-122

93 Flurazepam. **2020**, 321-324

92 Cyamemazine. **2020**, 201-206

91 Amphetamine (D). **2020**, 39-44

90 Amitriptyline. **2020**, 25-32

89 Clorazepate. **2020**, 185-190

88 Clonidine. **2020**, 179-184

87 Caprylidene. **2020**, 127-130

86 Fluoxetine. **2020**, 301-306

85 Eszopiclone. **2020**, 285-288

84 Bremelanotide. **2020**, 95-98

83 Mirtazapine. **2020**, 509-514

82 Midazolam. **2020**, 499-502

81 Milnacipran. **2020**, 503-508

80 Chlorpromazine. **2020**, 153-158

79 Flibanserin. **2020**, 289-292

78 Loxapine. **2020**, 443-450

77 Fluphenazine. **2020**, 313-320

76 Clomipramine. **2020**, 165-172

75 Fluvoxamine. **2020**, 325-330

74 Modafinil. **2020**, 521-526

73 Lorazepam. **2020**, 437-442

72	Amisulpride. <b>2020</b> , 17-24	
71	Benzotropine. <b>2020</b> , 85-88	
70	Lamotrigine. <b>2020</b> , 387-394	
69	Lofexidine. <b>2020</b> , 427-430	
68	Bremelanotide for Treatment of Female Hypoactive Sexual Desire.. <b>2022</b> , 14, 75-88	3
67	Safety Profile of Bremelanotide Across the Clinical Development Program.. <b>2022</b> , 31, 171-182	
66	Prescriber's Guide. <b>2020</b> ,	7
65	Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management.. <b>2022</b> ,	
64	Accidental Flibanserin Ingestion in Children Causing Acute Respiratory and Central Nervous System Depression: What Health Care Professionals Need to Know.. <b>2022</b> ,	0
63	Development and validation of a novel evaporation setup-assisted TLC method with fluorescence detection for determination of flibanserin in pharmaceutical and biological samples.. <b>2022</b> , 1195, 123204	1
62	Emphasis on the incorporation of Tropaeolin OO dye and silver nanoparticles for voltammetric estimation of flibanserin in bulk form, tablets and human plasma.. <b>2022</b> , 245, 123420	1
61	Loflazepate. <b>2020</b> , 431-436	
60	Assessing the Burden of Illness Associated with Acquired Generalized Hypoactive Sexual Desire Disorder.. <b>2022</b> ,	1
59	Zolpidem. <b>2020</b> , 871-874	
58	Pipothiazine. <b>2020</b> , 633-638	
57	Thioridazine. <b>2020</b> , 759-764	
56	Vortioxetine. <b>2020</b> , 853-858	
55	Prazosin. <b>2020</b> , 643-646	

54 Temazepam. **2020**, 755-758

53 Index by Drug Name. **2020**, 895-910

52 Quetiapine. **2020**, 667-676

51 Rivastigmine. **2020**, 699-704

50 Triiodothyronine. **2020**, 813-816

49 Index by Class. **2020**, 919-922

48 Zuclopenthixol. **2020**, 889-894

47 Tranylcypromine. **2020**, 787-792

46 Protriptyline. **2020**, 657-662

45 Index by Use. **2020**, 911-918

44 Reboxetine. **2020**, 681-686

43 Sulpiride. **2020**, 741-746

42 Zopiclone. **2020**, 879-882

41 Trifluoperazine. **2020**, 803-808

40 Ziprasidone. **2020**, 863-870

39 Triazolam. **2020**, 799-802

38 Perphenazine. **2020**, 607-612

37 Topiramate. **2020**, 781-786

- 36 Trazodone. **2020**, 793-798
- 35 Tiagabine. **2020**, 771-776
- 34 Vilazodone. **2020**, 847-852
- 33 Risperidone. **2020**, 687-698
- 32 Phenelzine. **2020**, 613-618
- 31 Valproate. **2020**, 829-836
- 30 Varenicline. **2020**, 837-840
- 29 Pitolisant. **2020**, 639-642
- 28 Sertraline. **2020**, 721-728
- 27 Pregabalin. **2020**, 647-652
- 26 Tasimelteon. **2020**, 751-754
- 25 Perospirone. **2020**, 601-606
- 24 Zonisamide. **2020**, 875-878
- 23 Trimipramine. **2020**, 817-824
- 22 Thiothixene. **2020**, 765-770
- 21 Valbenazine. **2020**, 825-828
- 20 Selegiline. **2020**, 705-714
- 19 Zaleplon. **2020**, 859-862

18 Tianeptine. **2020**, 777-780

17 Suvorexant. **2020**, 747-750

16 Sodium oxybate. **2020**, 733-736

15 Pimozide. **2020**, 627-632

14 solriamfetol. **2020**, 737-740

13 Zotepine. **2020**, 883-888

12 Pimavanserin. **2020**, 623-626

11 Phentermine/topiramate. **2020**, 619-622

10 Trihexyphenidyl. **2020**, 809-812

9 Propranolol. **2020**, 653-656

8 Venlafaxine. **2020**, 841-846

7 Quazepam. **2020**, 663-666

6 Sertindole. **2020**, 715-720

5 Paroxetine. **2020**, 593-600

4 Sildenafil. **2020**, 729-732

3 Ramelteon. **2020**, 677-680

2 Modeling Female Sexual Desire: An Overview and Commentary. ○

1 LIGANDY RECEPTORA 5-HT1A JAKO POTENCJALNE LEKI PRZECIWDOPRESYJNE. **2015**, 13, 28-39 ○

